companies / exai-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 1,300,0001.3M | ○ |
|---|---|---|
| founded | null | |
| hq | palo alto, ca, usa | |
| industry | unknown | |
| stage | null |
Exai Bio is developing an RNA-based liquid-biopsy platform that uses proprietary oncRNA biomarkers plus AI to detect early-stage cancer from a blood draw. Customers are clinicians and care pathways looking for non-invasive multi-cancer screening or recurrence monitoring. The team's pitch is finding cancer signals in what looks like noise to other platforms.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-01-01 | grant | 1,300,0001.3M | null | ○ |
Cloudflare, Google Analytics, Google Font API, Google Hosted Libraries, Google Tag Manager, jsDelivr, WordPress, PHP, MySQL, jquery 3.5.1
| fact | status | src |
|---|---|---|
| Grant, $1.3M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes